Journal article

RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors

Sherene Loi, Sathana Dushyanthen, Paul A Beavis, Roberto Salgado, Carsten Denkert, Peter Savas, Susan Combs, David L Rimm, Jennifer M Giltnane, Monica V Estrada, Violeta Sanchez, Melinda E Sanders, Rebecca S Cook, Mark A Pilkinton, Simon A Mallal, Kai Wang, Vincent A Miller, Phil J Stephens, Roman Yelensky, Franco D Doimi Show all

Clinical cancer research : an official journal of the American Association for Cancer Research | AMER ASSOC CANCER RESEARCH | Published : 2016

Grants

Awarded by Susan G. Komen for the Cure Foundation


Awarded by NIH/NCI


Awarded by Breast Cancer Specialized Program of Research Excellence (SPORE)


Awarded by Vanderbilt-Ingram Cancer Center Support Grant


Funding Acknowledgements

J.M. Balko was supported by the Inflammatory Breast Cancer (IBC) Network Foundation, Susan G. Komen for the Cure Foundation CCR14299052, the NIH/NCI (1K99CA181491), the Breast Cancer Specialized Program of Research Excellence (SPORE) P50 CA098131, Vanderbilt-Ingram Cancer Center Support Grant P30 CA68485. C.L. Arteaga is also supported by Susan G. Komen for the Cure Foundation grant SAC100013. S. Loi, S. Dushyanthen, P.A. Beavis, P. Savas, and P.K. Darcy are supported by the National Breast Cancer Foundation of Australia. S. Loi is also supported by Cancer Council Victoria, Australia.